Substance P–Saporin for the Treatment of Intractable Pain
| Autor: | Douglas A. Lappi, Carl E. Noe, Arthur E. Frankel, Denise Higgins, Hugh Nymeyer |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Substance P-Saporin
genetic structures business.industry Substance P Pharmacology eye diseases Clinical trial 03 medical and health sciences Animal data chemistry.chemical_compound 0302 clinical medicine Allodynia chemistry 030202 anesthesiology Anesthesia Hyperalgesia Medicine Intractable pain medicine.symptom business Receptor 030217 neurology & neurosurgery |
| Zdroj: | Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins ISBN: 9783319468754 |
| DOI: | 10.1007/978-3-319-46877-8_6 |
| Popis: | Pain is a worldwide chronic health issue, and additional therapies are needed for the management of severe pain. Substance P–Saporin (SP-SAP) covalently links a biological toxin (SAP) and an endogenous peptide (SP) that targets that toxin to the subset of neurons expressing the NK1 receptor. SP-SAP, currently in phase I clinical trials, is unique as the only targeted toxin for pain to undergo human testing. We review the history of SP-SAP and related NK1-receptor targeted toxins. We review animal data on the safety and efficacy of SP-SAP for the treatment of pain in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor. Finally, we discuss possible mechanisms of action of SP-SAP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|